Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836521 | 0.89 | GHSR (0.64) | GHSRDRD2SMN1; SMN2CXCR5ALDH1A1 | |
| SCHEMBL5835274 | 0.88 | GHSR (0.65) | GHSRDRD2CXCR5ALDH1A1KDM4E | |
| SCHEMBL5835047 | 0.85 | GHSR (0.46) | GHSRDRD2SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL5196233 | 0.80 | GHSR (0.61) | GHSRDRD2 | |
| SCHEMBL18614234 | 0.78 | GHSR (0.63) | GHSRDRD2CXCR5 | |
| SCHEMBL2813574 | 0.78 | GHSR (0.63) | GHSRDRD2CXCR5 | |
| SCHEMBL29715495 | 0.78 | GHSR (0.63) | GHSRDRD2CXCR5 | |
| SCHEMBL5835049 | 0.75 | GHSR (0.46) | GHSRDRD2SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL5835834 | 0.75 | GHSR (0.54) | GHSRDRD2CXCR5KDM4E | |
| SCHEMBL5835139 | 0.75 | GHSR (1.00) | GHSRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885DRD2 3220/4885AAK1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.